NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-339-2002-0-PCT-02 Method And Apparatus For Performing Multiple Simultaneous Manipulations of Biomolecules In A Two-Dimensional Array PCT PCT PCT/US2003/037208 Expired
NIDCR E-033-2004-0-US-01 Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof US 60/523,602 Abandoned
NCI E-031-2003-0-PCT-02 Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2 PCT PCT PCT/US03/37065 Expired
NCI E-031-2003-0-EP-04 Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2 EP National Stage 03796431.9 Abandoned
NHLBI E-120-2003-1-US-01 METHOD OF INDUCING MEMORY B CELL DEVELOPMENT AND TERMINAL DIFFERENTIATION US 60/523,754 Abandoned
NCI E-037-2004-0-US-01 Glycoproteins tagged with Galactose at the free N-acetylglucosamine Moieties and Methods of Synthesis thereof US 60/523,112 Abandoned
NCI E-031-2003-0-AU-05 Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2 AU National Stage 2003298677 Abandoned
NCI E-031-2003-0-CA-06 Immunogenic Epitopes For Fibroblast Growth Factor 5 (FGF-5) Presented By HLA-A3 And HLA-A2 CA National Stage 2506684 Abandoned
NCI E-177-2003-0-PCT-01 Boosting Thymus Function By Inhibiting The Function Of The Gene, SPATIAL, Its Products, Or The Pathways By Which It Regulates Thymic Functions PCT PCT PCT/US03/36874 Expired
NCI E-282-2000-0-US-07 Analogs of Thalidomide as Potential Angiogenesis Inhibitors US National Stage 10/469,359 7320991 Abandoned PDF
NICHD E-184-2001-1-US-02 Modified Growth Hormone US National Stage 10/477,651 7271150 Abandoned PDF
NHLBI E-035-2003-0-PCT-02 Variable Curve Catheter PCT PCT PCT/US2003/036210 Expired
NHLBI E-010-2003-0-PCT-02 Method and Device For Catheter-Based Repair of Cardiac Valves PCT PCT PCT/US03/36617 Expired
NLM E-111-2004-0-US-01 Methods, Articles, And Compositions For Identifying Oligonucleotides US 60/519,911 Abandoned
NHLBI E-035-2003-0-EP-04 Variable Curve Catheter EP National Stage 37833389.4 Abandoned
NICHD E-043-2003-0-PCT-04 Biomarkers for Intra-Amniotic Inflammation PCT PCT PCT/US03/36622 Abandoned
NICHD E-043-2003-0-US-03 Methods and Kits for Determining Risk of Pre-Term Delivery US ORD 10/713,791 Abandoned
NHLBI E-037-2003-1-PCT-01 METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE PCT PCT COMB PCT/US03/36317 Expired
NCI E-219-2002-2-US-01 METHODS OF INHIBITING METASTASIS OR GROWTH OF A TUMOR CELL US CIP 10/706,265 Abandoned
NCI E-088-2005-0-US-01 System For Treating And Preventing Breast Cancer US 60/519,427 Abandoned
NCI E-087-2005-0-US-01 Custom Vectors For Treating And Preventing Pancreatic Cancer US 60/519,354 Abandoned
NICHD E-191-2001-0-PCT-02 GP64-Pseudotyped Vectors and Uses Thereof PCT PCT PCT/US03/35728 Abandoned
NIAID E-324-2003-0-US-01 Streptococcus Lipoprotein Antigens US 60/519,028 Abandoned
NCI E-294-2002-0-CA-06 A New Target for Angiogenesis and Anti-Angiogenesis Therapy CA National Stage 2504953 Abandoned
NIAID E-178-1999-2-US-01 Production of Attenuated, Human-Bovine Chimeric Respiratory Syncytial Viruses Vaccines US CIP 10/704,116 7820182 Abandoned PDF
NCI E-294-2002-0-AU-05 A New Target for Angiogenesis and Anti-Angiogenesis Therapy AU National Stage 2003295422 Abandoned
NCI E-294-2002-0-PCT-02 A New Target for Angiogenesis and Anti-Angiogenesis Therapy PCT PCT PCT/US03/35633 Expired
NCI E-294-2002-0-EP-04 A New Target for Angiogenesis and Anti-Angiogenesis Therapy EP National Stage 03786608.4 Abandoned
NIAMS E-277-2003-0-US-01 Stimulation or Inhibition of Gamma Delta T-Cells to Promote or Inhibit Bone Growth US 60/518,278 Abandoned
NHLBI E-320-2002-1-US-01 DETECTION OF MUTATIONAL FREQUENCY AND RELATED METHODS US CIP 10/704,283 7255993 Expired PDF
NCI E-149-2001-0-US-02 Novel Nitric Oxide Releasing Imidate And Thioimidate Diazeniumdiolates Compositions, Uses Thereof And Method of Making Same US DIV 10/702,849 7105502 Abandoned PDF
NCI E-249-2002-0-PCT-02 Smallpox Vaccine Regimen PCT PCT PCT/US03/35499 Expired
NCI E-061-1999-1-US-02 Polypeptides Comprising IL-6 Ligand-Binding Receptor Domains US DIV 10/702,765 7144986 Abandoned PDF
NCI E-325-2003-0-PCT-01 Biofunctionalized Quantum Dots for Biological Imaging PCT PCT PCT/US2003/034897 Expired
NIAID E-250-2002-0-PCT-02 Safer Attenuated Virus Vacines with Missing or Diminished Latency of Infection PCT PCT PCT/US03/35167 Abandoned
NIAID E-304-1998-0-US-03 Recombinant ORF2 Proteins of the Swine Hepatitis E virus and their use as a Vaccine and as a Diagnostic Reagent for Medical and Veterinary Applications US National Stage 10/476,777 Abandoned
NHGRI E-012-2004-0-US-01 SNPs Near HNF4A Are Associated With Type 2 Diabetes Susceptibility US 60/517,662 Abandoned
NHLBI E-189-1989-3-US-04 GENE THERAPY US REISSUE 10/701,022 39788 Expired PDF
NCI E-070-2001-0-US-07 Chemical Compounds And Methods US National Stage 10/466,769 Abandoned
NHLBI E-060-2004-0-US-01 Genetic Variation In The Estrogen Receptor, ESR1, Is Associated With Risk For Myocardial Infarction And Cardiovascular Evetns US 60/517,425 Abandoned
NIDCR E-114-2003-0-US-01 Methods and Compositions for the Inhibition of HIV-1 Replication US 60/516,734 Abandoned
NCI E-099-1989-0-US-29 METHODS FOR IDENTIFYING ALPHA PDGFR AGONISTS AND ANTAGONISTS US CON 10/700,249 7252929 Abandoned PDF
NCI E-248-2002-0-PCT-02 Methods and Compositions For the Diagnosis of Neuroendocrine Lung Cancer PCT PCT PCT/US03/34787 Expired
NCI E-248-2002-0-EP-03 Methods and Compositions For the Diagnosis of Neuroendocrine Lung Cancer EP National Stage 3772056.6 Abandoned
NIDDK E-068-2004-0-US-06 MVL, AN ANTIVIRAL PROTEIN FROM A CYANOBACTERIUM US National Stage 10/592,422 7964559 Abandoned PDF
NIAID E-090-1996-0-US-06 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION US CON 10/700,313 7151087 Abandoned PDF
NCI E-022-2003-0-US-01 Methods for Treating Retroviral Infections and Retroviral Inhibitors Suitable for Use in Same US 60/515,987 Abandoned
NCI E-086-2003-0-US-01 Compositions and Methods For Inhibiting Translation of a Chimeric Gene US ORD 10/698,070 7553822 Abandoned PDF
CC E-008-2003-0-PCT-02 Scavenger Receptor B1 (CLA-1) Targeting For The Treatment Of Infection, Sepsis And Inflammation PCT PCT PCT/US03/34511 Expired
NIAID E-240-2002-0-PCT-02 HTLV-1-CELL BINDING AND INHIBITION PCT PCT PCT/US03/35431 Expired